Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 18279103)


Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.

Zeytin H, Reali E, Zaharoff DA, Rogers CJ, Schlom J, Greiner JW.

J Interferon Cytokine Res. 2008 Feb;28(2):73-87. doi: 10.1089/jir.2007.0063.


IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.

Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP, Ferrini S.

J Immunol. 2004 Feb 1;172(3):1540-7.


The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.

Hance KW, Rogers CJ, Zaharoff DA, Canter D, Schlom J, Greiner JW.

Clin Cancer Res. 2009 Apr 1;15(7):2387-96. doi: 10.1158/1078-0432.CCR-08-1752. Epub 2009 Mar 10.


Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.

Kim KD, Choi SC, Kim A, Choe YK, Choe IS, Lim JS.

Int Immunopharmacol. 2001 Nov;1(12):2117-29.


ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.


An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.

Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.

Int Immunol. 2006 Mar;18(3):425-34. Epub 2006 Jan 13.


NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-γ and perforin-dependent mechanisms.

Ge MQ, Ho AW, Tang Y, Wong KH, Chua BY, Gasser S, Kemeny DM.

J Immunol. 2012 Sep 1;189(5):2099-109. doi: 10.4049/jimmunol.1103474. Epub 2012 Aug 6.


A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo.

Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ.

J Immunol. 2002 May 1;168(9):4472-9.


Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.

Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H.

Cancer Res. 2000 Sep 1;60(17):4838-44.


Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O.

Mol Ther. 2002 May;5(5 Pt 1):609-16.


Antitumor activity of IFN-lambda in murine tumor models.

Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T.

J Immunol. 2006 Jun 15;176(12):7686-94.


Fowlpox-based survivin vaccination for malignant mesothelioma therapy.

Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, Siccardi A, Carbone M.

Int J Cancer. 2013 Aug 1;133(3):612-23. doi: 10.1002/ijc.28048. Epub 2013 Feb 25.


Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells.

Thibodeaux DK, Hunter SE, Waldburger KE, Bliss JL, Trepicchio WL, Sypek JP, Dunussi-Joannopoulos K, Goldman SJ, Leonard JP.

J Immunol. 1999 Nov 15;163(10):5257-64.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk